Precipio Announces Q1 2026 Financial Results

Precipio, Inc. (NASDAQ: PRPO) reported Q1-2026 revenue of $6.71M, essentially flat compared to Q4-2025, driven by timing dynamics including delayed product shipments and CMS cuts. Adjusted EBITDA declined to $(0.16)M from $0.96M in Q4-2025, impacted by lower gross profits, new hiring costs, and bonus payments. Management attributes the flat performance to temporary factors and expects second-half growth from an expanding product pipeline developed by the newly hired commercial team.

05/14/2026, 5:00 PM • GlobeNewswire

Management team’s 2025 market-based Options have vested

Precipio, Inc. (NASDAQ: PRPO) announced that 2025 employee stock options for management vested after the company's stock price increased 400% to a 10-day VWAP of $30.30 from the grant price of $6.06. The company replaced traditional time-based vesting with market-based vesting to align management incentives with shareholder interests. A similar structure was implemented for 2026 options with a target price of $40, resulting in an $800,000 non-cash stock compensation expense in Q1 2026.

05/13/2026, 5:00 PM • GlobeNewswire

Precipio Announces Q1-2026 Shareholder Update Call

Precipio, Inc. (NASDAQ: PRPO), a specialty cancer diagnostics company, announced it will host its Q1-2026 shareholder update call on May 18th, 2026, at 5:00 PM ET. The call will feature management remarks on core businesses and will mark the first time the company incorporates a dedicated moderated live Q&A session into its quarterly update call, demonstrating the company's commitment to shareholder transparency and engagement.

05/06/2026, 5:00 PM • GlobeNewswire

Precipio Announces Q4 and year-end 2025 Shareholder Update Call

Precipio, Inc. (NASDAQ: PRPO), a specialty cancer diagnostics company, announced a corporate update call scheduled for April 2, 2026, to discuss Q4 and year-end 2025 results. The company reported preliminary unaudited revenues of $24.0M for 2025, representing a 30% year-over-year increase. Additionally, Precipio published a joint study with Memorial Sloan-Kettering Cancer Center on its Bloodhound BCR::ABL1 assay in the Journal of Clinical Pathology.

03/12/2026, 5:00 PM • GlobeNewswire

Precipio Takes Major Steps Toward a Clean Balance Sheet

Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced significant balance sheet improvements by repaying a $1.1 million advance from Change Healthcare and completing the exercise of all financial warrants issued in 2023. The company now maintains a nearly debt-free balance sheet with only an $80,000 Connecticut state loan remaining, positioning itself to focus on profitable operations and shareholder value creation.

01/15/2026, 9:00 AM • GlobeNewswire

Precipio to Showcase its BCR::ABL1 panel at 2025 ASH (American Society of Hematology) Meeting

Precipio conducted a comprehensive study with Memorial Sloan Kettering Cancer Center, evaluating their BCR::ABL1 assay using 895 patient samples. The study demonstrated superior performance and positive impacts on patient care and laboratory workflows.

12/05/2025, 10:00 AM • GlobeNewswire

Precipio Announces Q3-2025 Shareholder Update Call

Specialty cancer diagnostics company Precipio will host its Q3-2025 corporate update call on November 17th, 2025 at 5:00 PM ET, providing updates on its core businesses and diagnostic technologies.

11/04/2025, 5:00 PM • GlobeNewswire

Precipio Announces its Q2-2025 Financial Results

Precipio reported Q2-2025 revenues of $5.7M, a 27% year-over-year increase, with improvements in both Products and Pathology Services divisions. The company expects to end the year cash flow positive and debt-free, driven by revenue growth and cost management.

08/13/2025, 5:00 PM • GlobeNewswire

Precipio Enters Into Agreement With Warrant Holder To Exercise Majority Of Warrants As Cashless

Precipio has modified its warrant exercise structure, reducing potential share dilution and receiving approximately $1.2M in cash by changing the exercise method for 300,000 warrants.

07/11/2025, 4:30 PM • GlobeNewswire